Previous 10 | Next 10 |
Can-Fite BioPharma (NYSE:CANF), a clinical-stage biopharmaceutical company, is trading ~3% lower in the pre-market Tuesday after announcing a delay for a key data readout for the company’s lead candidate Piclidenoson from a late-stage trial in psoriasis. Piclidenoson, an oral...
Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that top line data from its Phase III Comfort™ study of Picliden...
Namodenoson met primary endpoint in Phase IIa NASH study by reducing liver fat, inhibiting fibrosis, and demonstrating anti-inflammatory effect Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary sm...
Piclidenoson has been out-licensed for the indication of psoriasis in certain major markets Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer...
Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and liver diseases, announced today that it will hold one-on-one virtual investor meetings during the J.P. Morgan Health...
Q1 2022: Psoriasis Phase III Data & Commencement of Enrollment in Phase IIb NASH H1 2022: Commencement of Enrollment in Phase III Liver Cancer Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of pro...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Can-Fite BioPharma (NYSEMKT: CANF ) is certainly a stock to keep an eye on this week. Shares of CANF stock opened higher by 16.7% on Wednesday after the company reported positive results from a Phase 2 clinical trial...
As they say, the early bird gets the worm, and there are no worms quite like penny stocks. Thanks to even the slightest catalyst, these cheap shares can spike hundreds of percentage points within a single day. While not all penny stocks trade during premarket hours, you’re su...
ShiftPixy (NASDAQ:PIXY) +53%. MingZhu Logistics Holdings (NASDAQ:YGMZ) +44% on share purchase agreement to acquire CheYi Network. Pop Culture Group (NASDAQ:CPOP) +17%. Can-Fite BioPharma (NYSE:CANF) +17% to file for patents after new findings for liver cancer therapy. Orch...
Can-Fite BioPharma (NYSE:CANF) ADRs have surged ~16.6% in the pre-market after the company announced that it was filing new patent applications in several countries for the treatment of all advanced solid tumors following the Phase 2 data for its liver drug Namodenoson. The decision...
News, Short Squeeze, Breakout and More Instantly...
Can-Fite Biopharma Ltd Sponsored ADR Company Name:
CANF Stock Symbol:
NYSE Market:
Can-Fite Biopharma Ltd Sponsored ADR Website:
RAMAT GAN, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, invites investors to a webinar on August 8...
PETACH TIKVA, Israel, July 11, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that it has submitted ...
Liver cirrhosis treatment global market is estimated to reach $29.2 billion by 2030 Ramat Gan, Israel, July 01, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that addr...